Rob Coker

3 weeks ago | themedicinemaker.com | Rob Coker

Did you know that gastroesophageal reflux disease (GERD) remains one of the most prevalent gastrointestinal disorders worldwide, with significant implications for healthcare systems and patient quality of life? Understanding the evolving landscape of GERD pathophysiology, diagnosis, and treatment can help identify therapeutic gaps and innovation opportunities. GERD is a common but complex condition.

3 weeks ago | themedicinemaker.com | Rob Coker

Sanofi intends to acquire Blueprint Medicines in a transaction valued at up to $9.5 billion, comprising $129.00 per share in cash and a contingent value right of up to $6.00 per share tied to regulatory milestones. The acquisition will give Sanofi full rights to Ayvakit (avapritinib), currently the only approved treatment for both advanced and indolent systemic mastocytosis, which generated $479 million in revenue in 2024.

3 weeks ago | themedicinemaker.com | Rob Coker

The field of oncology has witnessed a tectonic shift in recent years, driven by the rise of advanced therapies. At the forefront are chimeric antigen receptor T-cell (CAR T) therapies – personalized, living drugs that have redefined treatment paradigms for hematological malignancies. As their clinical efficacy garners headlines, however, a more sobering reality persists: health systems are not yet fully equipped to deliver on their promise.

3 weeks ago | themedicinemaker.com | Rob Coker

Veteran musical icon Art Garfunkel recently shared the story of his lifelong struggle with psoriasis for the first time. Throughout his career, he managed to conceal the condition using various treatments, including creams and UV light therapies, which provided only temporary relief. The persistent discomfort eventually led him to step back from performing during his legendary partnership with songwriter Paul Simon.

1 month ago | themedicinemaker.com | Rob Coker

The Trump administration continues to approach life sciences in much the same way as a bull approaches a china shop; this time by reportedly pulling a $590 million federal contract with Moderna on the development of an mRNA-based bird flu vaccine. The contract, agreed at the end of the Biden administration, was part of a broader initiative to bolster US pandemic preparedness.